YMAB(Delisted)
Y-mAbs Therapeutics (YMAB) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Y-mAbs Therapeutics market cap is -- and enterprise value is --.
Share Statistics
Y-mAbs Therapeutics has 45.44M shares outstanding, with a free float of 34.49M.
Valuation Ratios
Y-mAbs Therapeutics's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Solvency
Y-mAbs Therapeutics debt-to-equity ratio is -- and debt-to-assets ratio is 0.25.
Liquidity
Y-mAbs Therapeutics's current ratio is 4, quick ratio is 3.58, and cash ratio is 2.71, showing its short-term liquidity position.
Return on Capital
Y-mAbs Therapeutics's ROE is -24.31%, ROA is -17.01%, and ROIC is -28.72%, showing its return on capital profile.
Profitability
Y-mAbs Therapeutics gross margin is 81.78%, operating margin is -31.21%, and net margin is -26.03%.
Cost Structure
Y-mAbs Therapeutics spends 53.69% of revenue on R&D and 59.01% on SG&A.
Operating Efficiency
Y-mAbs Therapeutics's asset turnover is 0.65, inventory turnover is 1.71, and receivables turnover is 4.5, indicating its operating efficiency.
Income Statement
Y-mAbs Therapeutics's revenue is 85.39M, gross profit is 69.83M, net income is -22.22M, and EBITDA is -26.30M.
Balance Sheet
Y-mAbs Therapeutics's total debt is 0, net debt is 0, total equity is 87.49M, and cash is 62.29M.
Cash Flow Statement
Y-mAbs Therapeutics's operating cash flow is -17.80M, free cash flow is -17.92M, and CapEx is --.
Dividends & Yields
Y-mAbs Therapeutics dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Y-mAbs Therapeutics's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A company that develops novel antibody-based therapeutic products for the treatment of cancer
Per Share Metrics
Y-mAbs Therapeutics's EPS is -0.5, book value per share is 1.93, and free cash flow per share is --.
